
Co-Diagnostics (CODX) Earnings Dates & Reports
Co-Diagnostics (CODX) Most Recent Earnings
Report Date
Period EndingQ3 2025
Est. EPS-$0.19
Actual EPS-$0.16
EarningsBeat
Co-Diagnostics (CODX) Earnings
View the latest Co-Diagnostics (CODX) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares
Co-Diagnostics (CODX) Earnings per Share (EPS) History
Signup for full accessBrowse free
Co-Diagnostics (CODX) Latest Earnings
The value each CODX share was expected to gain vs. the value each share gained.
Co-Diagnostics (CODX) reported its most recent earnings on for Q3 2025, posting earnings per share (EPS) of -$0.16. This exceeded analysts' expectations of -$0.19 by 15.79%, marking a Beat.
For comparison, Co-Diagnostics reported EPS of -$0.32 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.12.
Co-Diagnostics (CODX) Earnings History
Co-Diagnostics (CODX) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Co-Diagnostics’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
Co-Diagnostics (CODX) Earnings FAQs
Co-Diagnostics (CODX) last reported earnings on Nov 13, 2025 for Q3 2025, posting an EPS of -$0.16, which Beat the estimate of -$0.19 by 15.79%.
For Q3 2025, Co-Diagnostics (CODX) reported an EPS of -$0.16, exceeding analysts' estimate of -$0.19 by 15.79%.
For Q3 2025, Co-Diagnostics (CODX) Beat expectations with an actual EPS of -$0.16 vs. an estimated EPS of -$0.19.
Following the last earnings report on Nov 13, 2025, Co-Diagnostics (CODX)'s stock price moved — from — to —.
The next Co-Diagnostics (CODX) earnings call is scheduled for Mar. 26, 2026, where executives will discuss financial results and outlook.